Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBloomsbury Regulatory News (BMY)

Share Price Information for Bloomsbury (BMY)

Share Price is delayed by 15 minutes
Get Live Data
665.00    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 2.00 (0.301%)
Market Cap: £541.28m
BMY Live PriceLast checked at - London Stock Exchange

Intraday Bloomsbury Share Chart

Acquisition

2 Jun 2021 12:17

RNS Number : 6090A
Bloomsbury Publishing PLC
02 June 2021
 

BLOOMSBURY PUBLISHING PLC

("Bloomsbury" or "the Company")

Bloomsbury acquisition strengthens Consumer division: Acquisition of Head of Zeus Limited

 2 June 2021

Bloomsbury Publishing Plc (LSE: BMY), the leading independent publisher, today announces that it has completed the acquisition of the issued share capital of Head of Zeus Limited ("Head of Zeus", "HoZ" or the "Acquisition"). The total valuation is £8.45 million, including payments of pre-existing loans. The consideration, net of pre-existing loans, is £7.35 million, of which £5.5 million will be satisfied in cash at completion, with £1.1 million payable in cash post completion, subject to working capital and other considerations, and £0.75 million of deferred consideration payable in cash subject to achievement of revenue, profit and Netflix release targets.

Head of Zeus is an independent publisher of genre fiction and narrative non-fiction and children's books, based in London. It has published many bestsellers, won literary prizes and industry awards. Its best-selling authors include Dan Jones, Cixin Liu, Victoria Hislop, and Lesley Thomson, and Elodie Harper, whose The Wolf Den went last week to number 5 in The Times bestseller list. Cixin Liu's bestselling science fiction trilogy, The Three-Body Problem, is being adapted for Netflix by David Benioff and D.B. Weiss, creators of HBO's Game of Thrones.

This acquisition will provide a strong addition to Bloomsbury's thriving Consumer division and support our long term Consumer growth strategy, with new high quality authors and effective publishing across all formats, including e-book and audio.

HoZ generated £8.6 million* of revenue in the year ended 31 December 2020, and profit before tax of £0.3 million*, with net assets of £4.6 million*.

Nigel Newton, Chief Executive of Bloomsbury, commented:

"Head of Zeus's entrepreneurial and innovative approach to publishing, and its wide range of trade titles, will make a strong addition to Bloomsbury's own. Bloomsbury will be able to provide the scale and digital platforms to boost Head of Zeus' success while operating as an independent imprint within the Bloomsbury Consumer division. We look forward to welcoming Head of Zeus' great authors and talented staff to Bloomsbury and working with them in the years to come."

Anthony Cheetham, Chairman, Head of Zeus commented:

"After nine vigorous years as an independent publisher, I believe that Head of Zeus, our authors, our staff and our shareholders have found the right long term home for our company with Bloomsbury.

I have known Nigel Newton for more than thirty years. We share many of the same values: creative publishing, unique content and beautiful books. And an entrepreneurial spirit that values innovation above conformity. Bloomsbury Publishing Plc is itself unique as the only British book publisher listed on the London Stock Exchange.

I would like to express my gratitude to all our stakeholders for their support since Head of Zeus was launched in 2012, and my thanks to Bloomsbury for opening the door to further growth and opportunity in the years ahead."

*Audited.

 

For further information, please contact:

Bloomsbury Publishing Plc

 

Nigel Newton, Chief Executive

nigel.newton@bloomsbury.com

Penny Scott-Bayfield, Group Finance Director

penny.scott-bayfield@bloomsbury.com

Hudson Sandler

+44 (0) 20 7796 4133

Dan de Belder / Rebekah Chapman

bloomsbury@hudsonsandler.com

 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the company's obligations under Article 17 of MAR.

The information in this announcement has not been audited or otherwise independently verified and no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herein. None of the Company or any of its affiliates, advisors or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss whatsoever arising from any use of this announcement, or its contents, or otherwise arising in connection with this announcement.

This announcement does not constitute or form part of any offer or invitation to sell, or any solicitation of any offer to purchase any shares in the Company, nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract or commitment or investment decisions relating thereto, nor does it constitute a recommendation regarding the shares of the Company.

Certain statements, statistics and projections in this announcement are or may be forward looking. By their nature, forward‑looking statements involve a number of risks, uncertainties or assumptions that may or may not occur and actual results or events may differ materially from those expressed or implied by the forward-looking statements. Accordingly, no assurance can be given that any particular expectation will be met and reliance should not be placed on any forward-looking statement. Accordingly, forward-looking statements contained in this announcement regarding past trends or activities should not be taken as representation that such trends or activities will continue in the future. You should not place undue reliance on forward-looking statements, which are based on the knowledge and information available only at the date of this announcement's preparation.

The Company does not undertake any obligation to update or keep current the information contained in this announcement, including any forward‑looking statements, or to correct any inaccuracies which may become apparent and any opinions expressed in it are subject to change without notice.

References in this announcement to other reports or materials, such as a website address, have been provided to direct the reader to other sources of information on Bloomsbury Publishing Plc which may be of interest. Neither the content of Bloomsbury's website nor any website accessible by hyperlinks from Bloomsbury's website nor any additional materials contained or accessible thereon, are incorporated in, or form part of, this announcement.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQUUAARAOUNRAR
Date   Source Headline
3rd Mar 20257:00 amRNSNotice of Trading Update
24th Feb 20254:27 pmRNSHolding(s) in Company
14th Feb 202510:05 amRNSBLOCK LISTING SIX MONTHLY RETURN
24th Jan 20257:00 amRNSBloomsbury reaches new agreement with Amazon
16th Dec 202410:05 amRNSHolding(s) in Company
16th Dec 20249:55 amRNSHolding(s) in Company - Replacement
11th Dec 202410:24 amRNSDirector/PDMR Shareholding
9th Dec 20249:18 amRNSDirector/PDMR Shareholding
26th Nov 202411:44 amRNSHolding(s) in Company
26th Nov 202410:35 amRNSDirector/PDMR Shareholding
24th Oct 20247:00 amRNSUnaudited Interim Results
30th Sep 20247:00 amRNSNotice of Interim Results
2nd Sep 202411:31 amRNSDirector/PDMR Shareholding
29th Aug 20247:00 amRNSDirector/PDMR Shareholding
28th Aug 202410:57 amRNSDirector/PDMR Shareholding
16th Aug 20244:18 pmRNSAMENDMENT: BLOCK LISTING SIX MONTHLY RETURN
16th Aug 20249:42 amRNSBLOCK LISTING SIX MONTHLY RETURN
7th Aug 20245:36 pmRNSAwards under the 2023 Executive Share Plan
16th Jul 20243:41 pmRNSResults of the 2024 Annual General Meeting
16th Jul 20247:00 amRNSAGM Trading Update
14th Jun 20245:01 pmRNSAnnual Financial Report
14th Jun 20241:48 pmRNSBoard Appointment
29th May 20247:00 amRNSAcquisition
23rd May 20247:00 amRNSChairman Succession Announcement
23rd May 20247:00 amRNSAudited Preliminary Results
20th May 20247:00 amRNSInvestor Presentation
16th Feb 20247:00 amRNSBLOCK LISTING SIX MONTHLY RETURN
14th Feb 20247:00 amRNSTrading Update
1st Feb 20243:11 pmRNSBloomsbury launches latest Sarah J. Maas novel
15th Jan 20247:00 amRNSBloomsbury Appoints Head of Investor Relations
12th Jan 202411:45 amRNSHolding(s) in Company
9th Jan 20244:10 pmRNSDirector/PDMR Shareholding
7th Dec 20237:00 amRNSTrading Update
15th Nov 20237:00 amRNSBlocklisting Application
31st Oct 20237:00 amRNSInvestor Presentation
26th Oct 20237:00 amRNSUnaudited Interim Results
9th Oct 20231:00 pmRNSBloomsbury playwright Jon Fosse wins Nobel Prize
22nd Sep 20231:26 pmRNSDirector/PDMR Shareholdings - Correction
14th Sep 20237:00 amRNSBloomsbury launches new book by Katherine Rundell
5th Sep 20237:00 amRNSDirector/PDMR Shareholding
1st Sep 20232:05 pmRNSDirector/PDMR Shareholding
30th Aug 20231:56 pmRNSDirector/PDMR Shareholding
29th Aug 20232:11 pmRNSDirector/PDMR Shareholding
23rd Aug 20237:00 amRNSHolding(s) in Company
22nd Aug 20238:00 amRNSBloomsbury enjoys bestseller success
17th Aug 20234:40 pmRNSBLOCK LISTING SIX MONTHLY RETURN
18th Jul 20235:13 pmRNSResults of the 2023 Annual General Meeting
18th Jul 20237:00 amRNSAGM Trading Update
23rd Jun 20232:29 pmRNSAnnual Financial Report
2nd Jun 202311:50 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.